Tagged with

polski holding farmaceutyczny (PHF) Polski Holding Farmaceutyczny (PHF) was put together in 2004 as a capital group consisting of three leading Polish pharma producers and the mission given by the State Treasury Minister was to privatise the three entities. You joined in March 2008, at a time when, if I may say, major steps…

Polpharma SA For years Polpharma has been the market leader in Poland. In many countries the arrival of multinational companies (MNCs) led to the loss of leadership by the historical players to the benefit of MNCs. How has the arrival of GSK, Teva or Sandoz, altered the playing field for the company…

Teva Italy Mr. Medda, Teva’s Italian history is relatively young, could you describe the main facts that describe Teva presence in Italy? Teva Italia was founded in 1996 and is currently the leading generic pharmaceutical company in Italy. So, the company has experienced rapid growth in the emerging generic market over the…

Servier Brasil When we met Servier Brazil five years ago the company had major ambitions: ‘grow more than 10% for the five following years’. How have these expectations turned out to be? Actually, these projections turned out to be quite conservative. In the last two years Servier has doubled its Brazilian revenues…

Novartis Argentina When we met with Javier Lombar at IMS Argentina, he was explaining how a lot of multinational companies are using Argentina as a regional base of operations. Novartis is a prime example of this. Could you explain how Novartis operates in a Latin American context, and what role the Argentinean…

INFARMA Until very recently originator drugs had a very weak presence in central and east European countries including Poland, and there was no real patent legislation. Nevertheless, Poland has changed and become an attractive market for innovators. Could you give us an idea of how the market for innovative drugs has…

Roemmers Roemmers fue establecida en 1921. ¿Cómo paso de ser una empresa familiar a la empresa que es hoy, y cuáles han sido los desafíos en el cambio en la cultura de la empresa? La crisis económica que sufrió Argentina en 2002, sirvió como catalizador para un cambio radical en Roemmers,…

Octapharma Brazil Mr. Mauricio, you’ve mentioned that Brazil is a different kind of market for Octapharma, one strongly based on price, and that because of this it’s hard to add value. Could you delve a bit deeper and elaborate on this point? Before delving into the Brazilian market situation, it is important…

JOSWE With forty years of experience behind your belt, you founded JOSWE in 2000. What were the opportunities in the market that you saw to establish the company at such a late stage? We studied the market and found that some product lines were not being produced in Jordan yet, for…

Česká asociace farmaceutických firem (ČAFF) Dr. Zörner, can you please begin by introducing our readers to the CAFF (Czech Association of Pharmaceutical Firms), and explicate its key activities and mission? We represent 24 companies in the Czech pharmaceutical industry that are mainly involved in the generics business. Our mission is to promote the generics industry,…

  Indochina’s biggest pharmaceutical market (US$ 4 billion, 66 million population, <5 percent of GDP spent on healthcare) has quickly matured over the past years due to the implementation of heavy cost containment measures meant to make healthcare more accessible to the patient. These measures have driven the market from…

State Institute for Drug Control (SUKL) Mr. Březovký, can you begin with an introduction to SUKL and its role within the Czech Republic’s complex regulatory environment? I would like to begin by noting that I have been at my position as director of SUKL from the 1st of May of this year—today, I have been six…